Clear Cell Carcinoma of the Ovary: a Retrospective Multicentre Experience of 254 Patients with Complete Surgical Staging

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Apr 28

PMID 16641903

Citations 97

Authors

M Takano

Y Kikuchi

N Yaegashi

K Kuzuya

M Ueki

M Suzuki

J Kigawa

S Takeuchi

H Tsuda

T Moriya

T Sugiyama

Affiliations

Soon will be listed here.

Abstract

A retrospective analysis was performed to evaluate the clinical characteristics and prognostic factors in the patients with clear cell carcinoma (CCC) of the ovary. After central pathological review and scanning of the medical records of nine Japanese institutions between 1992 and 2003, a total of 254 patients with CCC of the ovary were enrolled in the present study. Mean age was 52.4 years (range 23-73 years). Tumours were 13% (33/254) stage Ia, 36% (92/254) stage Ic, 13% (33/254) stage II, 30% (80/254) stage III, and 6% (16/254) stage IV. Five-year progression-free survival and overall survival was 84 and 88% in stage I, 57 and 70% in stage II, 25 and 33% in stage III and 0 and 0% in stage IV, respectively. Retroperitoneal lymph node metastasis was observed in 9% in pT1a tumours, 7% in pT1c tumours, 13% in pT2 tumours, and 58% in pT3 tumours, respectively. There was no survival benefit according to chemotherapeutic differences in the patients who received complete surgical staging procedures and conventional chemotherapy. Peritoneal cytological status was an independent prognostic factor in stage Ic patients (P=0.03) and only residual tumour diameter was an independent prognostic factor in stage III, IV patients (P=0.02). Our results suggest that cytoreductive surgery resulting in no residual tumour only could improve the prognosis of advanced CCC patients.

Citing Articles

Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma.

Saito R, Fukushima M, Sasaki M, Okamoto A, Ogiwara H NPJ Precis Oncol. 2025; 9(1):69.

PMID: 40074856 PMC: 11903656. DOI: 10.1038/s41698-025-00850-8.

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.

Rosso R, Turinetto M, Borella F, Chopin N, Meeus P, Laine A Oncologist. 2025; 30(1).

PMID: 39846983 PMC: 11756325. DOI: 10.1093/oncolo/oyae325.

Comparison of Treatment Outcomes Between First-Line Chemotherapy With or Without Bevacizumab for Advanced Ovarian Clear Cell Carcinoma (Tohoku Gynecologic Cancer Unit: TGCU-RS001A Study).

Shoji T, Takatori E, Nagasawa T, Kagabu M, Baba T, Shigeto T Cancers (Basel). 2024; 16(22).

PMID: 39594756 PMC: 11593229. DOI: 10.3390/cancers16223801.

Survival and biomarker analysis for cancer‑associated thromboembolism in ovarian clear cell carcinoma.

Ito T, Miyamoto M, Kishimoto N, Suminokura J, Hada T, Kakimoto S Mol Clin Oncol. 2024; 22(1):9.

PMID: 39583927 PMC: 11582522. DOI: 10.3892/mco.2024.2804.

Status and development of research on clear cell carcinoma of the ovary-a visualization-based bibliometric analysis.

Chen C, Ren W, Pei L, Sun J, Bai T Transl Cancer Res. 2024; 13(6):2950-2970.

PMID: 38988907 PMC: 11231787. DOI: 10.21037/tcr-23-2351.

References

Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M . Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer. 1998; 83(8):1555-60. View

Crozier M, Copeland L, Silva E, Gershenson D, Stringer C . Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol. 1989; 35(2):199-203. DOI: 10.1016/0090-8258(89)90043-7. View

Trimbos J, Vergote I, Bolis G, Vermorken J, Mangioni C, Madronal C . Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003; 95(2):113-25. View

Kanazawa K, Suzuki T, Tokashiki M . The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol. 1999; 73(2):237-41. DOI: 10.1006/gyno.1999.5349. View

Bray F, Loos A, Tognazzo S, La Vecchia C . Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer. 2004; 113(6):977-90. DOI: 10.1002/ijc.20649. View

Ho C, Chien T, Shih B, Huang S . Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol. 2003; 88(3):394-9. DOI: 10.1016/s0090-8258(02)00156-7. View

Tsuda H, Ito Y, Ohashi Y, Wong K, Hashiguchi Y, Welch W . Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005; 11(19 Pt 1):6880-8. DOI: 10.1158/1078-0432.CCR-05-0751. View

Edwards B, Brown M, Wingo P, Howe H, Ward E, Ries L . Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97(19):1407-27. DOI: 10.1093/jnci/dji289. View

Shimizu Y, Umezawa S, Hasumi K . A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singap. 1999; 27(5):650-6. View

10.

Kennedy A, Biscotti C, HART W, Webster K . Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989; 32(3):342-9. DOI: 10.1016/0090-8258(89)90637-9. View

11.

Behbakht K, Randall T, Benjamin I, Morgan M, King S, Rubin S . Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998; 70(2):255-8. DOI: 10.1006/gyno.1998.5071. View

12.

Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H . Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol. 2004; 94(1):161-6. DOI: 10.1016/j.ygyno.2004.04.023. View

13.

Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N . Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002; 100(2):281-7. DOI: 10.1016/s0029-7844(02)02040-9. View

14.

Cass I, Li A, Runowicz C, Fields A, Goldberg G, Leuchter R . Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001; 80(1):56-61. DOI: 10.1006/gyno.2000.6027. View

15.

Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K . Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology. 2003; 65(1):29-36. DOI: 10.1159/000071202. View

16.

OBrien M, Schofield J, Tan S, Fryatt I, Fisher C, Wiltshaw E . Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol. 1993; 49(2):250-4. DOI: 10.1006/gyno.1993.1117. View

17.

Leitao Jr M, Boyd J, Hummer A, Olvera N, Arroyo C, Venkatraman E . Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am J Surg Pathol. 2004; 28(2):147-59. DOI: 10.1097/00000478-200402000-00001. View

18.

Kita T, Kikuchi Y, Kudoh K, Takano M, Goto T, Hirata J . Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary. Oncol Rep. 2000; 7(2):327-31. DOI: 10.3892/or.7.2.327. View

19.

Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S . Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res. 2002; 93(6):723-8. PMC: 5927055. DOI: 10.1111/j.1349-7006.2002.tb01312.x. View

20.

Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T . Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000; 88(11):2584-9. View